Reformulation of a thermostable broadly protective recombinant vaccine against human papilloma virus

The causal relationship between Human Papilloma Virus (HPV) infection and cervical cancer has motivated the development, and further improvement, of prophylactic vaccines against this virus. 70% of cervical cancers, 80% of which in low-resources countries, are associated to HPV16 and HPV18 infection, with 13 additional HPV types, classified as high-risk, responsible for the remaining 30% of tumors. Current vaccines, Cervarix® (GlaxoSmithKline) and Gardasil®(Merk), are based on virus-like particles (VLP) obtained by self-assembly of the major capsid protein L1. Despite their undisputable immunogenicity and safety, the fact that protection afforded by these vaccines is largely limited to the cognate serotypes included in the vaccine (HPV 16 and 18, plus five additional viral types incorporated into a newly licensed nonavalent vaccine) along with high production costs and reduced thermal stability, are pushing the development of 2nd generation HPV vaccines based on minor capsid protein L2. The increase in protection broadness afforded by the use of L2 cross-neutralizing epitopes, plus a marked reduction of production costs due to bacterial expression of the antigens and a considerable increase in thermal stability could strongly enhance vaccine distribution and usage in low-resource countries. Previous studies from our group identified three tandem repeats of the L2 aa. 20-38 peptide as a strongly immunogenic epitope if exposed on the scaffold protein thioredoxin (Trx). The aim of this thesis work is the improvement of the Trx-L2 vaccine formulation with regard to cross-protection and thermostability, in order to identify an antigen suitable for a phase I clinical trial. By testing Trx from different microorganisms, we selected P. furiosus thioredoxin (PfTrx) as the optimal scaffold because of its sustained peptide epitope constraining capacity and striking thermal stability (24 hours at 100°C). Alternative production systems, such as secretory Trx-L2 expression in the yeast P. pastoris, have also been set-up and evaluated as possible means to further increase production yields, with a concomitant reduction of production costs. Limitations in immune-responsiveness caused by MHC class II polymorphisms –as observed, for example, in different mouse strains- have been overcome by introducing promiscuous T-helper (Th) epitopes, e.g., PADRE (Pan DR Epitope), at both ends of PfTrx. This allowed us to obtain fairly strong immune responses even in mice (C57BL/6) normally unresponsive to the basic Trx-L2 vaccine. Cross-protection was not increased, however. I thus designed, produced and tested a novel multi-epitope formulation consisting of 8 and 11 L2(20-38) epitopes derived from different HPV types, tandemly joined into a single thioredoxin molecule (“concatemers”). To try to further increase immunogenicity, I also fused our 8X and 11X PfTrx-L2 concatemers to the N-terminus of an engineered complement-binding protein (C4bp), capable to spontaneously assemble into ordered hepatmeric structures, previously validated as a molecular adjuvant. Fusion to C4bp indeed improved antigen presentation, with a fairly significant increase in both immunogenicity and cross-protection. Another important issue I addressed, is the reduction of vaccine doses/treatment, which can be achieved by increasing immunogenicity, while also allowing for a delayed release of the antigen. I obtained preliminary, yet quite encouraging results in this direction with the use of a novel, solid-phase vaccine formulation, consisting of the basic PfTrx-L2 vaccine and its C4bp fusion derivative adsorbed to mesoporus silica-rods (MSR).

La tutela brevettuale : dalle modificazioni in sede di esame alle limitazioni del titolo concesso

La limitazione del brevetto in corso di causa è uno dei temi più caldi ed attuali del contenzioso brevettuale, a seguito dell’introduzione nel Codice della Proprietà Industriale, con la riforma dell’agosto 2010, del 3° comma dell’art. 79, a mente del quale “In un giudizio di nullità, il titolare ha facoltà di sottoporre al giudice, in ogni stato e grado del giudizio, una riformulazione delle rivendicazioni che rimanga entro i limiti del contenuto della domanda di brevetto quale inizialmente depositata e non estenda la protezione conferita dal brevetto concesso”. L’applicazione della disposizione in discorso genera una serie di interrogativi, ai quali giurisprudenza e dottrina cercano di rispondere, e determina, e sempre più determinerà, un cambiamento radicale dello svolgimento del contenzioso brevettuale, con la possibilità di un “riassetto” della privativa, anche per successivi tentativi, nella quale anche il C.T.U. è spesso (e non senza contestazioni, a questo riguardo) parte attiva, non essendo infrequente che questo offra indicazioni circa la sussistenza di un margine di validità del titolo . L’elaborato tenta, quindi, di approfondire le problematiche di natura sostanziale e procedurale che l’articolo 79, comma 3, C.P.I. solleva, ripercorrendo con l’occasione le possibili facoltà di intervento sul brevetto, sia allo stato di domanda, che a seguito di concessione, che l’ordinamento mette a disposizione dell’inventore per perfezionare la propria privativa.